GSK’s Ris-Rez Meets Primary Endpoint In Phase III ARTEMIS-011 Trial, Reducing Risk Of Progression Or Death By 67%, Improving Median Progression-Free Survival To 5.5 Months Vs. 1.4 Months With Chemotherapy In Relapsed Or Refractory Osteosarcoma
Patients receiving Ris-Rez remained progression-free for a median of 5.5 months versus 1.4 months with comparatorSecond positive phase III trial in China adds to growing body of late-stage evidence for Ris-Rez in
GSK's new medicine Ris-Rez worked much better than old treatment for bone cancer. Patients stayed healthier about four times longer, which is a big win for the company.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.